한글목차

세계의 채플병 치료제 시장은 2025년에는 1억 4,530만 달러에 달하고, 2032년에는 1억 6,020만 달러에 이를 것으로 예측되고, 2025년부터 2032년에 걸쳐 CAGR 1.4%를 나타낼 것으로 전망됩니다.

그림. 채플병 치료제 시장 점유율(%), 지역별(2025년)

채플병은 DAF 또는 CD55 결손증으로도 알려져 있으며 면역계와 관련된 자연계에서는 드문 유전자 질환을 가리킵니다. 채플병 치료제 시장은 채플병을 관리하는 데 사용할 수 있는 치료 옵션을 의미합니다. 완치하는 치료법은 없으며, 치료는 증상의 관리와 삶의 질 향상을 목적으로 합니다. 연구자들은 미래에 질병의 진행을 지연시킬 수있는 새로운 약물 요법과 유전자 요법을 연구하고 있습니다.

시장 역학 :

세계의 채플병 치료제 시장은 신약이나 유전자 치료 개발을 위한 연구 투자 증가, 환자 지원 단체를 통한 질병 인지도의 향상, 신흥국의 의료비 증가 등에 의해 예측 기간 중에 꾸준한 성장이 예상됩니다. 치료법의 부족이 시장 확대를 억제할 가능성이 높습니다. 한편, 새로운 유전자 치료 접근법은 치료의 전망을 바꿀 가능성을 가지고 있으며, 시장 관계자에게 기회를 제공합니다.

본 조사의 주요 특징

• 본 보고서에서는 세계의 채플병 치료제 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측기간(2025-2032년) 시장 규모 및 복합연간 성장률(CAGR)을 제공합니다.
• 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
• 또한 시장 성장 촉진요인, 성장 억제요인, 기회, 신제품의 출시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
• 본 보고서에서는 세계의 채플병 치료제 시장에서 주요 기업을 기업 프로파일, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 파라미터에 기초하여 소개했습니다.
• 본 보고서로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 출시, 유형 업, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
• 세계의 채플병 치료제 시장 보고서는 투자자, 공급자, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해 관계자에 대응하고 있습니다.
• 이해관계자는 세계의 채플병 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• 일관된 기회 맵(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 주요 시장 기업 간의 파트너십 확대
  • 긴 승인 기간
  • 의료비 증가
• 주요 하이라이트
• 규제 시나리오
• 시장 동향
• PEST 분석
• PORTER 분석
• 제품 발매
• 합병, 인수 및 제휴

제4장 세계의 채플병 치료제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측의 분석
• 경제에 미치는 영향

제5장 세계의 채플병 치료제 시장, 유형별(2020-2032년)

• 에쿨리주맙
• 라불리주맙
• 베오포즈

제6장 세계의 채플병 치료제 시장, 진단별(2020-2032년)

• 위장 증상
• 부종
• 저알부민혈증
• 저감마글로불린혈증
• 영양실조

제7장 세계의 채플병 치료제 시장, 유통 채널별(2020-2032년)

• 소매 약국
• 병원 약국
• 온라인 약국

제8장 세계의 채플병 치료제 시장, 지역별(2020-2032년)

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제9장 경쟁 구도

• 기업 프로파일
  • Alexion Pharmaceuticals Inc.
  • Akari Therapeutics
  • Apellis Pharmaceuticals
  • Amgen Inc.
  • CinnaGen Co.
  • Novartis AG
  • Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals, Inc.

제10장 섹션

• 참고문헌
• 조사 방법
• 출판사에 대해

영문목차

Global Chaple Disease Therapeutics Market is estimated to be valued at USD 145.3 Mn in 2025 and is expected to reach USD 160.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 1.4% from 2025 to 2032.

Figure. Global Chaple Disease Therapeutics Market Share (%), By Region 2025

Chaple syndrome is also known as DAF or CD55 deficiency, which refers to a genetic disorder that is rare in nature and is related to the immune system. CHAPLE is an abbreviated form for 'CD55 deficiency with hyperactivation of angiopathic thrombosis, complement and severe protein-losing enteropathy (PLE)'. This disorder can be seen from childhood and could be fatal to the person. Chaple disease therapeutics market refers to the medical treatment options that are available for managing chaple disease. Chaple disease is a rare, chronic, and progressive neuromuscular disorder characterized by wasting and weakness of muscles. There is no cure for chaple disease and treatment aims to manage symptoms and improve quality of life. Some of the common treatment options include physical therapy to maintain strength and mobility, medications to relieve pain and muscle spasms, surgeries to insert tubes for delivering nutrition or breathing assistance, and bracing or adaptive devices to provide spinal support. Researchers are investigating new drug therapies and gene therapies which may slow the progression of disease in future. Global chaple disease therapeutics market is driven by growing prevalence of the disorder and rising demand for effective therapeutic solutions.

Market Dynamics:

Global chaple disease therapeutics market is expected witness steady growth during the forecast period due to increasing research investments for developing novel drugs and gene therapies, growing disease awareness through patient support organizations, and rising healthcare expenditures in developing nations. However, high costs that are associated with orphan drug development and lack of approved cure are likely to restrain market expansion. Meanwhile, emerging gene therapy approaches hold potential to alter the treatment landscape and provide opportunities for market players. Key market players are actively collaborating with research institutes to explore new targets and innovative treatment strategies.

Key features of the study:

• This report provides in-depth analysis of the global chaple disease therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chaple disease therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include Alexion Pharmaceuticals Inc., Akari Therapeutics, Apellis Pharmaceuticals, Amgen Inc., CinnaGen Co., Novartis AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., and Alnylam Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global chaple disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chaple disease therapeutics market

Detailed Segmentation:

• Global Chaple Disease Therapeutics Market, By Type
  • Eculizumab
  • Ravulizumab
  • Veopoz
• Global Chaple Disease Therapeutics Market, By Diagnosis
  • Gastrointestinal Symptoms
  • Edema
  • Hypoalbuminemia
  • Hypogammaglobulinemia
  • Malnutrition
• Global Chaple Disease Therapeutics Market, By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
• Global Chaple Disease Therapeutics Market, By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles
  • Alexion Pharmaceuticals Inc.
  • Akari Therapeutics
  • Apellis Pharmaceuticals
  • Amgen Inc.
  • CinnaGen Co.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Type
  • Market Snippet, By Diagnosis
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing partnerships among key market players
  • Long approval timelines
  • Rising healthcare expenditure
• Key Highlights
• Regulatory Scenario
• Market Trends
• PEST Analysis
• PORTER's Analysis
• Product Launches
• Mergers, Acquisitions, and Collaborations

4. Global Chaple Disease Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Chaple Disease Therapeutics Market, By Type, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Eculizumab
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Ravulizumab
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Veopoz
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Chaple Disease Therapeutics Market, By Diagnosis, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Gastrointestinal Symptoms
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Edema
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Hypoalbuminemia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Hypogammaglobulinemia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Malnutrition
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Chaple Disease Therapeutics Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Chaple Disease Therapeutics Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profile
  • Alexion Pharmaceuticals Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Akari Therapeutics
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Apellis Pharmaceuticals
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Amgen Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • CinnaGen Co.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Novartis AG
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Hoffmann-La Roche Ltd
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Regeneron Pharmaceuticals Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Alnylam Pharmaceuticals, Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Analyst Views

10. Section

• References
• Research Methodology
• About us